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Abstract
Objective: Parkinson’s disease (PD), Multiple System Atrophy (MSA) and
Progressive Supranuclear Palsy (PSP) are neurodegenerative diseases that can
be difficult to distinguish clinically. The objective of the current study was to use
surface-based analysis techniques to assess cortical thickness, surface area and
grey matter volume to identify unique morphological patterns of cortical atrophy in
PD, MSA and PSP and to relate these patterns of change to disease duration and
clinical features.
Methods: High resolution 3D T1-weighted MRI volumes were acquired from 14 PD
patients, 18 MSA, 14 PSP and 19 healthy control participants. Cortical thickness,
surface area and volume analyses were carried out using the automated surface-
based analysis package FreeSurfer (version 5.1.0). Measures of disease severity
and duration were assessed for correlation with cortical morphometric changes in
each clinical group.
Results: Results show that in PSP, widespread cortical thinning and volume loss
occurs within the frontal lobe, particularly the superior frontal gyrus. In addition,
PSP patients also displayed increased surface area in the pericalcarine. In
comparison, PD and MSA did not display significant changes in cortical
morphology.
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Conclusion: These results demonstrate that patients with clinically established
PSP exhibit distinct patterns of cortical atrophy, particularly affecting the frontal
lobe. These results could be used in the future to develop a useful clinical
application of MRI to distinguish PSP patients from PD and MSA patients.
Introduction
Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP) and
Parkinson’s disease (PD) are pathologically distinct neurodegenerative diseases
[1] that can be clinically indistinguishable, particularly in the early stages.[2, 3]
The majority of MSA and PSP cases are characterised by relentless disease
progression and carry a shortened life expectancy from onset of symptoms,
whereas PD is not associated with a substantial reduction in life expec-
tancy.[2, 4, 5] It is possible that these neurodegenerative diseases possess unique
morphological signatures, thus detection of sensitive and specific biomarkers may
prove useful in improving early diagnosis.
Neurodegenerative disorders are often associated with structural changes in the
brain and magnetic resonance imaging (MRI) holds the potential to detect subtle
variations in the volume and shape of subcortical regions, as well as cortical
morphometric changes such as cortical volume, thickness, area and folding
pattern, thus allowing the identification of objective diagnostic markers. Voxel-
based morphometry (VBM) is a neuroimaging analysis technique allowing whole
brain voxel-based investigation of focal changes in brain anatomy.[6] Studies
exploring regional brain volume differences in Parkinsonian syndromes have
revealed that the pathology of this disease is not confined to subcortical regions
but may also include atrophy of the cerebral cortex, in particular the frontal
cortex.[7–10] This frontal atrophy is especially prominent in PSP, often with a
distinct pattern of superior frontal atrophy.[8] Despite several studies indicating
the involvement of the cortex, the brain pathology underlying motor and non-
motor symptoms in parkinsonian syndromes is incompletely defined and
inferences are currently limited by the use of grey matter volume measurement.
Surface-based methods provide a sensitive tool for investigating cortical
atrophy by breaking down measures of local cortical volume into separate and
almost orthogonal components of thickness and surface area. While thickness
measures may provide some indication of underlying neuronal loss, reduced size
of neuronal cell bodies or degradation, surface area measures may reflect
underlying white matter fibers [11]; with tension or shrinkage of these fibers
leading to deeper sulci and extended area measures. In addition to increased
pathological specificity, cortical thickness and area measures provide a direct
index of cortical morphology that is less susceptible to variations in individual
positioning, as the extraction of the cortex follows the grey matter surface
regardless of positional variance.[12] Furthermore, cortical thickness measures
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have the advantage over voxel-based measures as they allow for sub-voxel
precision with thickness values being assigned to individual vertices rather than
voxels.[13] Studies combining measures of volume and surface-based methods
measuring cortical thickness and surface area have shown that both techniques
lead to similar findings but surface-based methods are able to provide more
sensitivity.[14]
Cortical atrophy is frequently regionally specific in disease and the progress of
atrophy can therefore reveal much about the evolution and causative factors of a
disease. Few studies have used surface-based methods to assess cortical
morphology in Parkinsonian syndromes, those that have, have focused on PD and
identified widespread regions of cortical thinning,[15, 16] however these studies
are not consistent with earlier reports of frontal atrophy. To our knowledge there
have been no previous studies comparing patterns of cortical change in PD, MSA
and PSP. Thus in this study we have chosen to measure cortical thickness, surface
area and cortical volume using the automated surface-based analysis package
FreeSurfer (Massachusetts General Hospital, Harvard Medical School; http://
surfer.nmr.mgh.harvard.edu).
It is not clear which affected cortical regions differ between these three diseases
and how this relates to differential clinical and cognitive symptoms. The aims of
the present study are firstly to identify regions of cortical atrophy that will enable
characterisation of each of the three diseases and secondly to discover whether
these regions relate to clinical or cognitive symptoms of the disease. Based on the
reviewed evidence, we hypothesise that along with clinical symptom severity, both
the MSA and PSP groups will display marked thinning and volume loss of the
cortex, particularly in frontal regions. We also hypothesise that the PD patients
will show subtle cortical changes that are more widespread across the whole
cortex.
Materials and Methods
Participants
Fourteen patients diagnosed with PSP, eighteen with MSA and fourteen with PD,
according to established criteria, [17–19] were recruited successively from the
Movement Disorders Clinic at King’s College Hospital and via referrals from
clinicians in south east England. Eleven probable MSA patients were categorised
as MSA-P (predominant parkinsonian features) and seven as MSA-C (pre-
dominant cerebellar features); both clinical variants of MSA were included since
the aim of this study was to explore the differences between cortical morphometry
in the three clinical groups in comparison to healthy controls, rather than the
variation between specific clinical variants. Of the fourteen PSP patients, thirteen
were classified as probable and one as possible.[2] All patients with PD fulfilled
criteria for definite PD [18] and sixteen MSA patients were categorised as
probable, one as possible and one as definite. Nineteen healthy controls matched
for age, were also recruited (spouses and friends of patients). The project was
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approved by research ethics committees of King’s Healthcare NHS Trust and the
Institute of Psychiatry and South London and Maudsley NHS Trust. Written
informed consent was given by all subjects before participation in the study.
Clinical and cognitive measures
Within 1 week of the MRI scan each participant was examined by the same
clinician (CB). Disease severity was measured using Hoehn and Yahr (H&Y),
Schwab and England activities of daily living (ADL) and Unified Parkinson’s
Disease Rating Scale Part III (UPDRS-III). Cerebellar ataxia and occulomotor
dysfunction were assessed using the Parkinson’s Plus Scale. Measures of global
cognitive function were also taken using the Mini-Mental State Examination
(MMSE) [20] and Mattis Dementia Rating Scale (DRS).[21]
Image acquisition
T1-weighted 3-dimensional (3D) inversion recovery prepared spoiled gradient
echo (SPGR) images were acquired from the whole brain on a 1.5T Signa LX NV/i
system (General Electric, Milwaukee, USA), fitted with actively shielded magnetic
field gradients (maximum amplitude 40 mTm 21) and a standard quadrature
birdcage head coil. Other parameters were TR518 ms; TE55.1 ms; TI5450 ms;
2566152 acquisition matrix over a 2406192 mm field of view (FOV),
reconstructed as a 2566256 over a 2406240 FOV, giving an in-plane pixel size of
0.937560.9375 mm; 12461.5 mm thick slices. Total scan time was 8 mins
20 sec.
Statistical Analysis
Clinical variables
Clinical variables were analysed using SPSS (version 20); one-way ANOVA with
post-hoc Tukey tests were used to assess between-group differences in age,
duration of disease, UPDRS, MMSE and DRS scores. The statistical threshold was
set at p ,0.05. Post-hoc t-tests were also performed to assess the difference in age
between the PSP group and each other group. A Kruskall-Wallis test was run to
determine if there were differences between H&Y, Schwab and England ADL, PPS
Occulomotor and Cerebellar scores between clinical groups. Pairwise comparisons
were performed using Dunn’s (1964) procedure with a Bonferroni correction for
multiple comparisons. Finally, a chi-square goodness-of-fit test was conducted on
gender.
Image Analysis
FreeSurfer analysis pipeline
Surface-based analysis was carried out using FreeSurfer version 5.1.0
(Massachusetts General Hospital, Harvard Medical School; http://surfer.nmr.mgh.
harvard.edu). The FreeSurfer pipeline performs cortical reconstruction and
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subcortical volumetric segmentation including the removal of non-brain tissue
(skull, eyeballs and skin), using an automated algorithm with the ability to
successfully segment the whole brain without any user intervention. This process
is based on a hybrid approach combining the robustness of a watershed algorithm
and the accuracy of deformable surface models. Automated Talairach transfor-
mation [22] is performed, followed by segmentation of the subcortical white
matter and deep grey matter structures; voxels are classified as white matter or not
based on intensity and neighbour constraints. Segmentation of deep grey matter
volumetric structures includes the hippocampus, amygdala, caudate, putamen
and ventricles [23] – although these structures were not used in the present study.
This is followed by intensity normalisation,[24] tessellation of the grey matter-
white matter boundary and the grey matter-CSF boundary, automated topology
correction [25, 26] and surface deformation following intensity gradients to
optimally place the grey/white and grey/cerebrospinal fluid borders at the location
where the greatest shift in intensity defines the transition to the other tissue
class.[13] On completion of the cortical models, individual cortical folding
patterns are then registered to a spherical atlas based on folding patterns, to match
cortical geometry across subjects.[27] Thickness can be calculated at each location
of the cortex as the distance between the white and pial surface.[13] The cerebral
cortex is then parcellated into units based on gyral and sulcal structure [23]
allowing local curvature and surface area measures to be computed. The current
study focused on cortical thickness, surface area and cortical volume – measures
that have recently been found to show significant change in Parkinsonian
syndromes.[7, 8, 28]
Cortical thickness, surface area and volume
Entire cortex analyses were computed to explore local cortical thickness, surface
area and cortical volume in PD, MSA, PSP and healthy control subjects. Statistical
maps were generated using FreeSurfer’s Query, Design, Estimate, Contrast
(QDEC) interface. QDEC is a single-binary application included in the FreeSurfer
distribution that is used to perform group averaging and inference on the cortical
morphometric data produced by the FreeSurfer processing stream. First, the three
diagnostic groups (PD, MSA, PSP) were compared with healthy controls (HC),
followed by comparison of the three clinical groups with each other. For each
hemisphere the General Linear Model (GLM) was computed vertex-by-vertex for
analysis of cortical thickness, surface area and cortical volume respectively,
accounting for the effects of gender and age to avoid spurious results. QDEC
provides two different methods for automatically creating a design matrix: DOSS
(different offset, same slope) and DODS (different offsets, different slopes). DOSS
assumes different morphometric measures for all groups (different offsets) and a
similar impact of disease duration in all clinical groups (same slope). DODS also
assumes different offsets but a different impact of duration between the clinical
groups (different slope). It is plausible that the diagnostic groups included in this
study will show different cortical evolution rates, thus DODS has been employed.
Cortical maps were smoothed using a 10 mm full width at half maximum
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Gaussian kernel and the results were visualised by overlaying significant cortical
areas onto semi-inflated cortical surfaces. Multiple comparisons were corrected
with a Monte Carlo Simulation using a p-value set at ,0.05.
Correlation between cortical, clinical and cognitive measures
The association between cortical morphometric measures and clinical measures in
each clinical group was also examined using QDEC. Disease duration, measures of
severity as measured by H&Y, Schwab and England ADL and UPDRS-III,
cerebellar ataxia and occulomotor dysfunction as measured by the Parkinson’s
Plus Scale and global cognitive function as measured by the DRS were included in
the analyses individually as continuous covariates. Age and gender were included
in these analyses as covariates of no interest.
Effect of cognitive impairment
Additional analyses were conducted to assess the effect of cognitive impairment
on between group differences in cortical atrophy. The DRS provides the most
comprehensive assessment of cognitive function of our cognitive measures, thus
patients with a DRS score below the cut-off threshold (DRS score # 125) were
classified as cognitively impaired and excluded from this particular analysis. Of
those excluded 5 were PSP patients and 2 MSA patients (n57).[29]
Results
Demographic and clinical variables
Diagnostic groups did not differ significantly in age, gender or disease duration in
one-way ANOVA analyses. However, post hoc t-tests showed that the PSP group
is significantly older than the MSA and HC groups. The PD group scored
significantly lower on measures of disease severity; H&Y (p#0.001), Schwab and
England ADL (p#0.001) and UPDRS III (p#0.001), the MSA group scored
significantly higher on measures of cerebellar function (p#0.001), while the PSP
group scored significantly higher on measures of occulomotor function
(p#0.001) and lower on MMSE (p#0.001) and DRS (p#0.001) (Table 1). A chi-
square goodness-of-fit test indicated that both genders were equally represented
by the participants recruited to the study (x2(1)50.015, p50.901).
Cortical thickness
PSP patients showed significant thinning of the frontal lobe, comprising the left
precentral, right lateral orbitofrontal and superior frontal gyri bilaterally when
compared to healthy controls (Figure 1, Table 2). When compared to the MSA
group, PSP patients displayed cortical thinning of the superior frontal gyrus
bilaterally (Figure 1, Table 2). Additional regions of cortical thinning in the left
rostral middle frontal gyrus, left caudal middle frontal gyrus and right superior
frontal gyrus were identified when PSP were compared with PD (Figure 1,
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Table 2). There were no significant regions of cortical thinning in the PD, MSA or
HC groups.
Surface area
PSP patients displayed significantly increased surface area in the left pericalcarine
when compared with the MSA group (Figure 2, Table 2). No regions of
significantly increased or decreased surface area were detected in PD, MSA or HC
groups.
Cortical volume
Cortical volume loss was detected in the superior frontal gyrus bilaterally in the
PSP group when compared with controls (Figure S1) and the right superior
frontal gyrus when compared with PD (Figure S1, Table S1). No significant
differences in volume were detected in the PD, MSA or HC groups.
Correlation between cortical and clinical measures
Spearman correlation analyses showed no significant correlation between any
clinical or cognitive measures with thickness, surface area or volume in any of the
subject groups.
Effect of cognitive impairment
Finally, when patients with DRS scores below the threshold of cognitive
impairment (DRS score # 125) were excluded from the between group analysis,
Table 1. Demographic and clinical data of control subjects and patients with PD, MSA and PSP.
Control
(n519) PD (n514) MSA (n518) PSP (n514)
p-value
(p,0.05)
Age (SD) 63.8 (7.9) 64.6 (6.9) 62.8 (7.2) 69.4 (7.2) 0.066
Sex, M:F 10:9 7:7 10:8 5:9 0.901
Disease duration (SD) NA 6.6 (2.0) 5.1 (2.5) 5.1 (2.1) 0.112
H&Y* median score (range) NA 2.5 (2.0–3.0) 3.0 (2.5–5.0) 4.0 (3.0–4.0) ,0.001
Schwab and England ADL* median score
(range)
NA 90% (80–100%) 70% (40–80%) 50% (20–80%) ,0.001
UPDRS III, (SD) NA 21.8 (9.6) 36.4 (13.2) 34.6 (8.0) ,0.001
Occulomotor Score, { median (range) NA 0.0 (0–3) 1.0 (0–5) 13.0 (7–20) ,0.001
Cerebellar Score, { median (range) NA 0.0 (0–2) 8.5 (0–13) 2.0 (0–6) ,0.001
DRS (SD) NA 140 (2.9) 136 (8.4) 127 (10.2) ,0.001
MMSE (SD) NA 29.5 (1.1) 28 (2.5) 26 (2.8) ,0.001
* For patients taking levodopa drug treatment, scores given in the ‘on’ state.
{From Parkinson’s Plus Scale (Cerebellar Score, maximum 24; Occulomotor Score, maximum 21).
MSA 5 multiple systems atrophy; PSP 5 progressive supranuclear palsy; PD 5 Parkinson’s disease; MSA-P 5 multiple system atrophy parkinsonian
variant; MSA-C 5 multiple system atrophy cerebellar variant; H&Y 5 Hoehn and Yahr; ADL 5 activities of daily living; UPDRS III 5 Unified Parkinson
Disease Rating Scale-part III.
doi:10.1371/journal.pone.0114167.t001
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results were very similar to the initial group comparisons, with widespread frontal
thinning remaining a significant result (Table S2).
Discussion
To our knowledge this is the first study to quantify and compare surface-based
measures in PD, MSA and PSP. Our results show that patients with PSP display
consistent thinning and volume loss of the superior frontal gyrus, as well as
thinning of the left precentral, rostral middle frontal, caudal middle frontal and
right lateral orbitofrontal gyri. Additionally, the left pericalcarine displayed a
significant increase in surface area in the PSP group. There were no significant
results in the MSA or PD groups. These findings support the hypothesis that PSP
patients display more clinically severe symptoms as well as differential and more
established patterns of cortical atrophy that particularly affects the frontal lobe.
The topographic pattern of cortical thinning and volume loss in the superior
frontal region seen here, is similar to that found in recent studies,[8, 30] reflecting
that the superior regions of the frontal lobe may be particularly targeted in PSP.
Previous functional imaging studies have also found abnormalities in this region
Figure 1. Cortical areas showing significant thinning in PSP patients compared to a) healthy controls,
b) Parkinson’s disease and c) Multiple System Atrophy; displayed on QDEC’s semi-inflated cortical
surfaces. Top row: L lateral and L medial, Second row: R lateral and R medial, Third row: anterior and
posterior, Bottom row: superior and inferior views. The colour bar indicates the significance levels of the
clusters. Results were obtained using Monte Carlo simulation, with a threshold of p ,0.05, to provide cluster-
wise correction for multiple comparisons.
doi:10.1371/journal.pone.0114167.g001
Table 2. Cortical regions displaying thinning of the cortex and increased surface area in PSP.
Contrast Region Coordinates Vertex Value Size
X, Y, Z (mm2)
Thickness
PSP—HC Left precentral gyrus 25.88, 2.49, 57.62 0 24.00 2212.57
Left superior frontal gyrus 30.06, 16.56, 43.15 2 22.85 1229.26
Right superior frontal gyrus 231.80, 60.96, 21.96 4 24.00 5516.95
Right lateral orbitofrontal gyrus 220.67, 56.64, 252.51 9 23.00 1236.09
PSP—MSA Left superior frontal gyrus 10.05, 30.67, 59.18 51 23.10 1283.04
Right superior frontal gyrus 231.80, 60.96, 21.96 4 24.00 3166.28
PSP—PD Left rostral middle frontal gyrus 21.20, 98.31, 26.90 55 23.52 1372.08
Left caudal middle frontal gyrus 223.55, 39.37, 22.68 94 23.10 1317.47
Right superior frontal gyrus 231.80, 60.96, 21.96 4 24.00 3043.13
Surface Area
PSP—MSA Left pericalcarine 24.95, 2100.10, 220.18 34 4.00 1864.52
X;Y;Z in Talairach coordinates. All results presented at the corrected threshold (p ,0.05).
MSA 5 Multiple Systems Atrophy; PSP 5 Progressive Supranuclear Palsy; PD 5 Parkinson’s Disease.
doi:10.1371/journal.pone.0114167.t002
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with reduced glucose metabolism in the superior half of the frontal lobes [31] and
reduced regional cerebral perfusion has been reported in a SPECT study.[32] It
may be interesting to highlight that the frontal lobe receives projections from
white matter tracts such as the superior cerebellar peduncle and superior
longitudinal fasciculus. While the results from this study show grey matter
thinning of frontal regions bilaterally, a loss of integrity of the superior cerebellar
Figure 2. Cortical areas showing significantly increased surface area in PSP patients compared to
Multiple System Atrophy; displayed on QDEC’s semi-inflated cortical surfaces. Top row: L lateral and L
medial, Second row: R lateral and R medial, Third row: anterior and posterior, Bottom row: superior and
inferior views. The colour bar indicates the significance levels of the clusters. Results were obtained using
Monte Carlo simulation, with a threshold of p ,0.05, to provide cluster-wise correction for multiple
comparisons.
doi:10.1371/journal.pone.0114167.g002
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peduncles has also been found in separate studies.[33, 34] Furthermore, previous
studies have shown deep grey matter structure degeneration [30] and loss of
integrity of various other white matter fibres [30, 34] - it is possible that in
degenerative diseases such as PSP, the build-up of subcortical tau deposition is
followed by white matter tract degeneration [30, 33] which subsequently causes
neuronal loss, reflected by thinning of the cortex. It would be beneficial for future
studies to combine surface-based measures with DTI measures to fully assess the
relationship between the cerebral cortex and white matter connectivity.
Results from this study also showed significantly increased surface area in the
pericalcarine cortex of the occipital lobe in the PSP group. It is noteworthy that
reduced fractional anisotropy (FA) reflecting loss of integrity has previously been
identified in the white matter of the pericalcarine in a population of PD patients;
this result was further correlated with poor cognitive flexibility. PSP patients often
display cognitive impairments similar to those seen in PD, although often in a
markedly more severe form [29, 35] (Table 1). Although the measures from the
pericalcarine did not correlate with cognitive measures in this study, when
cognitively impaired patients were excluded from the analysis, a significant
increase in surface area could no longer be seen in this region, therefore it is likely
that this result was driven by those cognitively impaired patients and thus related
to cognitive impairment.
Surprisingly, no changes were detected in the PD group after Monte Carlo
Simulation correction for multiple comparisons was applied. Previous studies
have reported inconsistent results in the pathology of PD, with some studies
reporting involvement of the frontal, occipital, parietal and temporal regions of
the cortex,[15, 36] whilst others report no significant differences.[7] Of these
studies finding significant atrophy in PD only Pereira and colleagues [15] were
able to identify regions of cortical thinning that were robust enough to survive
Monte Carlo Simulation. Considering this study made use of the same FreeSurfer
analysis pipeline, although an earlier version (version 4.3.1) and the group mean
age (64 years) was very close to that seen in the present study, it is likely that the
more robust findings seen in their study is due to the use of a 3T scanner as
opposed to a 1.5T scanner as used in the present study. 3T scanners allow a higher
signal-to-noise ratio (SNR) and increased spatial resolution; these improvements
in terms of image quality may allow more subtle differences in cortical
morphometry to be detected at the analysis stage.
To our knowledge this is the first study to assess cortical thickness and surface
area in an MSA population. Our results show that there are no significant regions
of cortical change in MSA patients, however a previous VBM study has identified
frontal and motor areas of volume loss in an MSA sample [7] – thus this patient
group needs further investigation with a larger sample size to increase the
statistical power. In addition, it is plausible that patients with MSA-P and MSA-C
display differential patterns of cortical atrophy in association with the different
symptoms shown in the MSA variants. Thus, it would be beneficial for future
studies to assess these two groups separately and compare the results with
differential patterns of symptoms seen between them.
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Overall, these results confirm that surface-based methods are a sensitive tool
with which to measure disease related changes of the cerebral cortex. In fact,
cortical thinning was observed in regions of the frontal lobe in the PSP group,
where neither volume loss nor surface area changes were detected. While there was
no significant change in surface area in the superior frontal gyrus it is plausible to
reason that the volume loss displayed here and potentially in previous volumetric
studies is driven by cortical thinning alone. These findings add support to the
concept that these morphometric measures are completely separate and may
reflect different pathological changes, thus emphasising the importance of
assessing cortical thickness and surface area as separate measures and reiterate the
focused sensitivity of surface-based methods.
The present study is advantageous over previous similar studies because it
includes data from three clinical groups included in a single study, however the
statistical power of the study would be increased with larger group sizes. In future
it would therefore be beneficial to recruit a larger sample of participants from each
clinical group. In addition, results may have been affected by the slightly older age
of the PSP patients, thus age was included as a nuisance factor in all analyses to
account for this difference. A final limitation of the study is that the spatial
resolution of the data used was not isotropic, thus there is a potential possibility
that subtle changes in the cortex may have gone unnoticed.
In conclusion, this study has identified widespread frontal atrophy in PSP, in
particular the superior frontal gyrus, enabling morphological differentiation of
this disease from PD and MSA at the clinically established disease stage. It may be
interesting in the future to extend these results by using similar methods to those
that have previously been employed in these patient groups [37, 38], this would
enable us to determine whether these patient groups could be correctly classified
based on the cortical atrophy seen in the current study, thus establishing the
potential for use in clinical practice.
Supporting Information
Figure S1. Cortical areas showing significant volume loss in PSP patients
compared to a) healthy controls, b) Parkinson’s disease; displayed on QDEC’s
semi-inflated cortical surfaces. Top row: L lateral and L medial, Second row: R
lateral and R medial, Third row: anterior and posterior, Bottom row: superior and
inferior views. The colour bar indicates the significance levels of the clusters.
Results were obtained using Monte Carlo simulation, with a threshold of p,0.05,
to provide cluster-wise correction for multiple comparisons.
doi:10.1371/journal.pone.0114167.s001 (TIF)
Table S1. Cortical regions displaying volume loss in PSP. X;Y;Z in Talairach
coordinates. All results presented at the corrected threshold (p ,0.05).
doi:10.1371/journal.pone.0114167.s002 (DOCX)
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Table S2. Cortical regions displaying thinning of the cortex and increased surface
area in PSP, excluding patients with a DRS score # 125. X;Y;Z in Talairach
coordinates. All results presented at the corrected threshold (p ,0.05).
doi:10.1371/journal.pone.0114167.s003 (DOCX)
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